227 related articles for article (PubMed ID: 34904810)
1. Poly(ADP-Ribose) Polymerase Inhibition in Small Cell Lung Cancer: A Review.
Guo MZ; Marrone KA; Spira A; Scott SC
Cancer J; 2021 Nov-Dec 01; 27(6):476-481. PubMed ID: 34904810
[TBL] [Abstract][Full Text] [Related]
2. PARP inhibitors in small cell lung cancer: The underlying mechanisms and clinical implications.
Wang X; Zeng X; Li D; Zhu C; Guo X; Feng L; Yu Z
Biomed Pharmacother; 2022 Sep; 153():113458. PubMed ID: 36076571
[TBL] [Abstract][Full Text] [Related]
3. [Highlights of PAPR Inhibitors in Small Cell Lung Cancer].
Zhang S; Liu J; Yang C; Zhang L; Li S; Bao H; Cheng Y
Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):806-810. PubMed ID: 32752582
[TBL] [Abstract][Full Text] [Related]
4. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
Xiong J; Barayan R; Louie AV; Lok BH
Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
[TBL] [Abstract][Full Text] [Related]
5. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
[TBL] [Abstract][Full Text] [Related]
6. Talazoparib Dual-targeting on Poly (ADP-ribose) Polymerase-1 and -16 Enzymes Offers a Promising Therapeutic Strategy in Small Cell Lung Cancer Therapy: Insight from Biophysical Computations.
Mgoboza C; Okunlola FO; Akawa OB; Aljoundi A; Soliman MES
Cell Biochem Biophys; 2022 Sep; 80(3):495-504. PubMed ID: 35588345
[TBL] [Abstract][Full Text] [Related]
7. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
[TBL] [Abstract][Full Text] [Related]
8. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
Dulaney C; Marcrom S; Stanley J; Yang ES
Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
[TBL] [Abstract][Full Text] [Related]
10. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Byers LA; Wang J; Nilsson MB; Fujimoto J; Saintigny P; Yordy J; Giri U; Peyton M; Fan YH; Diao L; Masrorpour F; Shen L; Liu W; Duchemann B; Tumula P; Bhardwaj V; Welsh J; Weber S; Glisson BS; Kalhor N; Wistuba II; Girard L; Lippman SM; Mills GB; Coombes KR; Weinstein JN; Minna JD; Heymach JV
Cancer Discov; 2012 Sep; 2(9):798-811. PubMed ID: 22961666
[TBL] [Abstract][Full Text] [Related]
11. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
12. Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
Gadgeel SM
Curr Treat Options Oncol; 2018 Sep; 19(11):53. PubMed ID: 30203184
[TBL] [Abstract][Full Text] [Related]
13. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
14. Targeting DNA damage in SCLC.
Foy V; Schenk MW; Baker K; Gomes F; Lallo A; Frese KK; Forster M; Dive C; Blackhall F
Lung Cancer; 2017 Dec; 114():12-22. PubMed ID: 29173760
[TBL] [Abstract][Full Text] [Related]
15. Extensive-stage small-cell lung cancer: Current management and future directions.
Yu Y; Chen K; Fan Y
Int J Cancer; 2023 Jun; 152(11):2243-2256. PubMed ID: 36346100
[TBL] [Abstract][Full Text] [Related]
16. What's new in small cell lung cancer - extensive disease? An overview on advances of systemic treatment in 2016.
Seeber A; Leitner C; Philipp-Abbrederis K; Spizzo G; Kocher F
Future Oncol; 2017 Jul; 13(16):1427-1435. PubMed ID: 28685608
[TBL] [Abstract][Full Text] [Related]
17. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
18. MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer.
Lai J; Yang H; Zhu Y; Ruan M; Huang Y; Zhang Q
BMC Cancer; 2019 Jun; 19(1):602. PubMed ID: 31215481
[TBL] [Abstract][Full Text] [Related]
19. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
Owonikoko TK; Zhang G; Deng X; Rossi MR; Switchenko JM; Doho GH; Chen Z; Kim S; Strychor S; Christner SM; Beumer J; Li C; Yue P; Chen A; Sica GL; Ramalingam SS; Kowalski J; Khuri FR; Sun SY
Cancer Med; 2014 Dec; 3(6):1579-94. PubMed ID: 25124282
[TBL] [Abstract][Full Text] [Related]
20. PARP and PARG inhibitors in cancer treatment.
Slade D
Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
